Vortex “As a clinician, I am excited about accessing the cancer biology of patient’s through CTCs. Vortex’s technology provides the best source of CTCs to aid in the diagnostic and treatment decisions we face every day.” – Dr. Jonathan Goldman, MD, Director of Clinical Trials in Thoracic Oncology, Associate Director of Drug Development at UCLA “Improving CTCs recovery along with high cellular purity while maintaining viability have tremendous value for translational research and clinical diagnostic applications. The VTX-1 holds the potential to revolutionize blood-based diagnostics.” - Pr. Massimo Cristofanilli, MD, FACP, Professor of Medicine, Associate Director of Translational Research and Precision Medicine, Robert H Lurie Comprehensive Cancer Center, Feinberg School of Medicine Wanda J. Cribbs, Lead Gartner Analyst Population Health & Analytics says: "Wanda's recent HRS press release really stands out. Delivering those results and having a client publicly share credit with their vendor is rare and says a lot. We at Gartner will have our eyes on Wanda in 2018"

Longevity Biotech

PDS is a clinical stage immunotherapy company developing a next-generation of simpler, safer and more effective immunotherapies for cancer and infectious diseases. Versamune® -its novel synthetic nanoparticle platform technology- activates multiple immunological mechanisms which direct the targeting of cancer and infectious disease by the immune system.

Developments

In May 2015 PDS announced positive preliminary data showing that its lead cancer immunotherapy treatment, PDS0101, has generated strong T-cell responses in pre-cervical cancer. In February 2016 PDS signed a Cooperative Research and Development Agreement with the National Cancer Institute, a division of the US National Institutes of Health. The goal is to co-develop novel cancer immunotherapies through Phase II clinical trials that will start in 2016 and 2017.

PDS has recently strengthened its senior management team with the recruitment of a Chief Medical Officer and VP of Drug Development and Manufacturing. NetScientific has invested £1.76m for a 14.85% shareholding in PDS.

Sector

Therapeutics – Cancer Immunotherapy

Management Team

Frank Bedo-Addo, CEO

Company HQ

North Brunswick, NJ, US

Website

www.pdsbiotech.com

Longevity Biotech - NetScientific